Detalhe da pesquisa
1.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Blood
; 141(13): 1610-1625, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36508699
2.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood
; 140(15): 1674-1685, 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960871
3.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood
; 139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995344
4.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767897
5.
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Am J Hematol
; 99(2): E32-E36, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994196
6.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
7.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med
; 383(26): 2526-2537, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369355
8.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
9.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Haematologica
; 108(7): 1768-1781, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519325
10.
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.
Future Oncol
; 19(30): 2029-2043, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37828901
11.
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Eur J Haematol
; 109(3): 257-270, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35634931
12.
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Blood
; 134(14): 1132-1143, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292114
13.
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Nature
; 519(7541): 102-5, 2015 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25686603
14.
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.
Blood
; 141(21): 2657-2661, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898087
15.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Invest New Drugs
; 38(5): 1448-1453, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125598
16.
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.
Haematologica
; 105(6): 1527-1538, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439679
17.
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Blood
; 130(6): 789-802, 2017 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28619982
18.
Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.
J Pediatr Hematol Oncol
; 41(7): e481-e483, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30045148
19.
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.
Blood
; 128(23): 2683-2693, 2016 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27621309
20.
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Haematologica
; 108(10): 2794-2798, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021540